You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)夥以色列藥企梯瓦(TEVA.US)共同開發腫瘤免疫療法
阿思達克 06-17 09:10
復星醫藥(02196.HK)公布,與以色列製藥公司梯瓦(TEVA.US)達成戰略合作,將通過各自子公司共同開發抗PD1-白細胞介素-2(IL2) ATTENUKINE療法TEV-56278。該產品是一種抗PD-1抗體-細胞因子融合蛋白,目前處於一期臨床試驗階段,開發適應症涵蓋黑色素瘤等多種癌症。 根據協議,復星醫藥將取得TEV-56278在中國(包括港澳台地區)及部分東南亞國家和地區的獨家開發、生產和商業化許可,梯瓦則保留TEV-56278在全球其他地區的權益。雙方將共享臨床數據,預期可加速研發進程。 復星醫藥執行總裁王興利指出,合作將整合梯瓦的創新藥物開發經驗,以及復星在腫瘤領域的臨床開發及商業化能力,相信可進一步強化復星醫藥在腫瘤免疫治療領域的佈局。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account